• Search
  • Advanced Search

Search

  • HOME
  • Search
Review
2100
Prospect of emerging treatments for hepatitis B virus functional cure
Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2025;31(Suppl):S165-181.   Published online November 14, 2024
View: 2547   Download: 379  Web of Science: 4  Crossref: 7
2151
Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0
Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T.F. Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Meifang Han, Weiming Yan, Hong Ren, Peng Hu, Sainan Shu, Paul Yien Kwo, Fu-sheng Wang, Man-Fung Yuen, Qin Ning
Clin Mol Hepatol. 2025;31(Suppl):S134-S164.   Published online January 22, 2025
View: 3198   Download: 386  Crossref: 1
Correspondence
Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”
Ji Won Han, Dae Won Jun
Clin Mol Hepatol. 2025;31(2):e152-e154.   Published online December 30, 2024
View: 1044   Download: 31
Letter to the Editor
Tacrolimus levels and variability in CKD and ESRD risk post-liver transplant: Letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Rui Shi, Minghua Wang
Clin Mol Hepatol. 2025;31(2):e137-e139.   Published online January 9, 2025
View: 848   Download: 44  Web of Science: 1  Crossref: 1
Editorial
Momentum towards simplifying and expanding treatment for chronic hepatitis B: The body of evidence continues to grow: Editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”
Robert J. Wong
Clin Mol Hepatol. 2025;31(2):603-605.   Published online October 29, 2024
View: 854   Download: 27  Web of Science: 1  Crossref: 1
Intrapatient variability of tacrolimus trough level may be not the cause, but an indirect parameter of comorbidities: Editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”
Jongman Kim
Clin Mol Hepatol. 2025;31(2):589-591.   Published online January 24, 2025
View: 848   Download: 39  Web of Science: 1  Crossref: 1
Letter to the Editor
Accountability in AI medicine: A critical appraisal of ChatGPT in patient self-management and screening
Jiawen Wang, Tian Xia
Clin Mol Hepatol. 2025;31(1):e1-e2.   Published online September 26, 2024
View: 1095   Download: 49
Correspondence
Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
Young Eun Chon, Dong Yun Kim, Hong Jae Chon, Do Young Kim
Clin Mol Hepatol. 2024;30(4):1005-1008.   Published online May 30, 2024
View: 1851   Download: 67
Editorial
Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”
Junjie Yu
Clin Mol Hepatol. 2024;30(4):721-723.   Published online June 18, 2024
View: 1758   Download: 66  Web of Science: 1
Original Article
1928
Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy
Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu
Clin Mol Hepatol. 2024;30(3):515-538.   Published online May 10, 2024
View: 5262   Download: 322  Web of Science: 6  Crossref: 6
1914
Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts
Shuai Wang, Xiaohong Lin, Yunhua Tang, Yichen Liang, Min Zhang, Zhonghao Xie, Yiwen Guo, Yuqi Dong, Qiang Zhao, Zhiyong Guo, Dongping Wang, Xiaoshun He, Weiqiang Ju, Maogen Chen
Clin Mol Hepatol. 2024;30(3):421-435.   Published online April 11, 2024
View: 3602   Download: 165  Web of Science: 3  Crossref: 4
Correspondence
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
Hyeyeon Hong, Jonggi Choi
Clin Mol Hepatol. 2024;30(2):272-273.   Published online February 21, 2024
View: 2719   Download: 86  Web of Science: 1  Crossref: 1
Letter to the Editor
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(1):121-123.   Published online December 4, 2023
View: 3082   Download: 95  Web of Science: 12  Crossref: 11
Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”
Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji
Clin Mol Hepatol. 2024;30(1):113-117.   Published online November 10, 2023
View: 3197   Download: 88  Web of Science: 5  Crossref: 4
Letter regarding “Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma”
Chi Hsiao, Yung-Po Liaw
Clin Mol Hepatol. 2024;30(1):109-110.   Published online October 11, 2023
View: 2321   Download: 53
Original Article
1868
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi‐Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang, Yi-Hsiang Huang, Lee-Won Chong, Chien-Lin Chen, Chi-Chieh Yang, Sheng‐Shun Yang, Pin-Nan Cheng, Tsai-Yuan Hsieh, Jui-Ting Hu, Wen-Chih Wu, Chien-Yu Cheng, Guei-Ying Chen, Guo-Xiong Zhou, Wei-Lun Tsai, Chien-Neng Kao, Chih-Lang Lin, Chia-Chi Wang, Ta-Ya Lin, Chih‐Lin Lin, Wei-Wen Su, Tzong-Hsi Lee, Te-Sheng Chang, Chun-Jen Liu, Chia-Yen Dai, Jia-Horng Kao, Han-Chieh Lin, Wan-Long Chuang, Cheng-Yuan Peng, Chun-Wei- Tsai, Chi-Yi Chen, Ming-Lung Yu, TACR Study Group
Clin Mol Hepatol. 2024;30(1):64-79.   Published online November 21, 2023
View: 6862   Download: 183  Crossref: 8
1867
Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide
Hyeyeon Hong, Won-Mook Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi
Clin Mol Hepatol. 2024;30(1):49-63.   Published online November 20, 2023
View: 4115   Download: 257  Web of Science: 12  Crossref: 11
Review
The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Landon L. Chan, Stephen L. Chan
Clin Mol Hepatol. 2023;29(4):909-923.   Published online May 25, 2023
View: 4507   Download: 282  Web of Science: 15  Crossref: 16
1798
Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm
Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao
Clin Mol Hepatol. 2023;29(4):869-890.   Published online March 14, 2023
View: 4965   Download: 233  Web of Science: 16  Crossref: 20
Original Article
1824
Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma
Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee
Clin Mol Hepatol. 2023;29(3):794-809.   Published online May 17, 2023
View: 4900   Download: 179  Web of Science: 2  Crossref: 1
1814
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, Peng-Sheng Ting, Hirsh Trivedi, Aarshi Vipani, Walid Ayoub, Ju Dong Yang, Omer Liran, Brennan Spiegel, Alexander Kuo
Clin Mol Hepatol. 2023;29(3):721-732.   Published online March 22, 2023
View: 28146   Download: 1,698  Web of Science: 344  Crossref: 355
Review
1774
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
Clin Mol Hepatol. 2023;29(3):593-604.   Published online February 13, 2023
View: 6999   Download: 401  Web of Science: 36  Crossref: 36
Letter to the Editor
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”
Chia-Ming Chu, Yun-Fan Liaw
Clin Mol Hepatol. 2023;29(2):510-512.   Published online January 30, 2023
View: 3601   Download: 78  Web of Science: 1  Crossref: 1
Review
1813
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Clin Mol Hepatol. 2023;29(2):242-251.   Published online March 20, 2023
View: 7818   Download: 261  Web of Science: 12  Crossref: 13
Original Article
1698
Hepatocellular carcinoma incidence is decreasing in Korea but increasing in the very elderly
Young Eun Chon, Seong Yong Park, Han Pyo Hong, Donghee Son, Jonghyun Lee, Eileen Yoon, Soon Sun Kim, Sang Bong Ahn, Soung Won Jeong, Dae Won Jun
Clin Mol Hepatol. 2023;29(1):120-134.   Published online August 12, 2022
View: 6961   Download: 247  Web of Science: 35  Crossref: 37
Editorial
Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip
Clin Mol Hepatol. 2023;29(1):113-117.   Published online October 31, 2022
View: 4137   Download: 118  Web of Science: 4  Crossref: 5
The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(1):99-101.   Published online October 27, 2022
View: 4667   Download: 92  Web of Science: 4  Crossref: 6
Guideline
1713
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea
Clin Mol Hepatol. 2022;28(4):583-705.   Published online October 1, 2022
View: 19376   Download: 853  Web of Science: 183  Crossref: 201
Review
1640
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
Pil Soo Sung
Clin Mol Hepatol. 2022;28(3):333-350.   Published online October 19, 2021
View: 19229   Download: 395  Web of Science: 32  Crossref: 35
Guideline
KASL clinical practice guidelines for management of chronic hepatitis B
The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol. 2022;28(2):276-331.   Published online April 1, 2022
View: 13837   Download: 645  Web of Science: 80  Crossref: 90
1 | 2 | 3 | 4 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 1641
TOTAL : 2789332
Close layer